1. Usulan rekomendasi
Diusulkan untuk direkomendasikan
Ranibizumab diusulkan untuk direkomendasikan untuk edema makula diabetik.
Alasan usulan
- Dibandingkan dengan laser makula, ranibizumab memberi tambahan 0,41 tahun hidup berkualitas (QALY) per pasien dengan tambahan biaya Rp 22,5 juta per pasien.
- Rasio biaya terhadap manfaat sebesar Rp 54,6 juta per QALY berada di bawah acuan satu kali PDB per kapita (Rp 75 juta per QALY).
2. Informasi tentang ranibizumab
| Nama generik | Ranibizumab |
|---|---|
| Kode ATC | S01LA04 |
| Bidang terapi | Organ indra |
| Program penilaian | Penilaian obat baru |
| Intervensi yang dinilai | Ranibizumab sesuai kebutuhan |
| Pembanding | laser makula |
| Formularium Nasional | Tercantum (FKRTL) |
| Izin edar BPOM | Ya |
| Katalog elektronik pengadaan | Ya |
| Daftar Obat Esensial WHO | Ya |
| Perluasan akses FKTP | Reasesmen 3: Hanya dijamin di FKRTL dan tercantum dalam Daftar Obat Esensial WHO, atau sudah memiliki penilaian teknologi kesehatan. |
| Biaya obat dalam model (per tahun atau per rangkaian terapi) | Rp 34 juta |
3. Pembahasan bukti
| Ukuran | Nilai |
|---|---|
| Tambahan tahun hidup berkualitas per pasien | 0,412 QALY |
| Tambahan biaya per pasien | Rp 22,5 juta |
| Rasio biaya terhadap manfaat | Rp 54,6 juta per QALY |
| Peluang hemat biaya pada Rp 75 juta per QALY | 72,4% |
Hasil lengkap, termasuk simulasi probabilistik dan analisis sensitivitas, tersedia pada halaman bukti.
Keterbatasan
Uraian berikut tersedia dalam bahasa Inggris.
- ADJUDICATED MODEL: base-case comparator is macular laser (NICE TA274 base comparator). The policy-relevant LMIC question of branded ranibizumab versus cheap off-label bevacizumab is addressed only as a secondary class-context arm and a scenario, where ranibizumab carries little or no incremental QALY (DRCR.net Protocol T) and would be hard to justify on cost-effectiveness grounds against bevacizumab.
- Drug acquisition costs (ranibizumab, bevacizumab, aflibercept) use procurement proxies, not verified Indonesian INAPROC/e-catalogue or Fornas prices; the ranibizumab year-1 cost depends heavily on the assumed number of injections (RESTORE mean ~7).
- The engine applies the year-1 drug course once; the chronic, declining multi-year injection burden of anti-VEGF therapy (and laser re-treatment) is therefore only partially captured and likely understates lifetime intervention cost.
- Vision-band transition probabilities are adapted from the NICE TA274/RESTORE model, not from an Indonesian DMO cohort; treatment effects are encoded as transition multipliers rather than the original month-by-month visual-acuity transition matrix.
- Disease-specific visual-impairment utilities use UK NICE/time-trade-off fallback decrements anchored to the Indonesian EQ-5D-5L general-population value set; Indonesia-specific vision EQ-5D decrements were unavailable.
- Care costs by vision band (especially severe-sight-impairment/blindness support) are INA-CBG-style estimates requiring direct Permenkes tariff validation.
- Single treated eye is modelled; NICE applied a ~1.5x factor for bilateral treatment, which would raise both QALYs and costs.
- The model assumes no excess mortality attributable to vision band (consistent with NICE TA274).
4. Implementasi
Dengan perkiraan 600.000 pasien yang memenuhi syarat, dampak anggaran kumulatif lima tahun diperkirakan tambahan belanja Rp 5,4 triliun. Rincian per tahun tersedia pada halaman implementasi.
Penilaian kapasitas layanan, kesiapan implementasi, dan kesetaraan belum tersedia untuk topik ini.
5. Tim penilai dan status telaah
| Status telaah | Draf, menunggu telaah ahli ekonomi kesehatan |
|---|---|
| Penyusun analisis | ARC Institute |
| Pengesahan komite | Belum ada |